HIVPhase 2NCT04311502
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
A Phase 2 study testing Rifapentine, Rifampicin and Isoniazid in people with HIV and Tuberculosis, run by National Institute of Allergy and Infectious Diseases (NIAID) at 6 sites in 5 countries.
Trial summary
The purpose of this study was to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV, Tuberculosis
- What is being tested?
- Rifapentine, Rifampicin and Isoniazid
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 6 sitesin 5 countries
- Study dates
- 5 Nov 2021to 24 Jun 2025
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:
- At least one sputum specimen positive for M. tuberculosis by molecular TB assay (Xpert) or line probe assay [LPA]) OR
- At least one sputum specimen positive (1+ or greater) for acid-fast bacilli (AFB) on smear microscopy
- Note: TB diagnosis for purposes of meeting inclusion criterion can be from a study testing laboratory or from an outside laboratory, as long as it is from a sputum sample collected within 5 days prior to entry.
- Pulmonary TB diagnosed without known INH resistance (e.g., by LPA or Xpert) and without known RIF resistance (e.g., by either LPA or Xpert).
- Absence of HIV-1 infection, as documented by any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, within 30 days prior to entry OR HIV-1 infection, documented by any licensed rapid HIV test or HIV-1 E/CIA test kit at any time prior to entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. Two or more HIV-1 RNA viral loads of >1,000 copies/mL are also acceptable as documentation of HIV-1 infection.
Show all 29Show fewer
- For participants living with HIV, CD4+ cell count ≥100 cells/mm^3, obtained within 30 days prior to study entry at any network-approved non-US laboratory that is Immunology Quality Assessment (IQA) certified.
- For participants living with HIV must be currently receiving or planning to initiate antiretroviral therapy (ART) at or before study week 8.
- A verifiable address or residence readily accessible to facilitate directly observed therapy (DOT), and willingness to inform the study team of any change of address during the treatment and follow-up period.
- The following laboratory values obtained at or within 5 days prior to entry by any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practice (GCLP) and participates in appropriate external quality assurance programs.
- Serum or plasma alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN)
- Serum or plasma total bilirubin ≤2.5 times ULN
- Serum or plasma creatinine ≤2 times ULN
- Serum or plasma potassium ≥3.5 mEq/L and ≤5.5 mEq/L
- Absolute neutrophil count (ANC) ≥650/mm^3
- Hemoglobin ≥7.0 g/dL
- Platelet count ≥50,000/mm^3
- For females of reproductive potential, negative serum or urine pregnancy test within 5 days prior to entry by any US clinic or laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or is using a point of care (POC)/CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with Good Clinical Laboratory Practice (GCLP) and participates in appropriate external quality assurance programs.
- Female participants of reproductive potential must agree not to participate in the conception process (i.e., active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must agree to use at least one reliable nonhormonal method of contraception, as listed below, while on study treatment and for 30 days after stopping study medications.
- Acceptable forms of contraception include:
- Condoms
- Intrauterine device or intrauterine system
- Cervical cap with spermicide
- Diaphragm with spermicide
- Note: Hormonal birth control alone is not acceptable, as it may not be sufficiently reliable in combination with RPT or RIF.
- Female participants who are not of reproductive potential must have documentation of menopause (i.e., at least 1 year amenorrheic), hysterectomy, or bilateral oophorectomy or bilateral tubal ligation.
- Documentation of Karnofsky performance score ≥50 within 30 days prior to entry.
- Documentation of either the presence or absence of advanced disease as determined by chest X-ray within 5 days prior to entry.
- Ability and willingness of participant to provide informed consent.
Who cannot join
- More than 5 days of treatment directed against active TB for the current TB episode preceding study entry.
- Pregnant or breast-feeding.
- Unable to take oral medications.
- Current receipt of clofazimine or bedaquiline or known receipt of clofazamine or bedaquiline at any time in the past.
- Corrected QT based on the Fridericia correction method (QTcF) interval >450 ms for men or >470 ms for women within 30 days prior to entry.
- Weight <30 kg.
Show all 13Show fewer
- Current or planned use within 6 months following enrollment of one or more of the following medications: HIV protease inhibitors, HIV entry and fusion inhibitors, HIV non-nucleoside reverse transcriptase inhibitors (other than EFV), elvitegravir/cobicistat, bictegravir, quinidine, procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or terfenadine.
- Current extrapulmonary TB, in the opinion of the site investigator.
- Current or history of known personal or family long QT syndrome.
- Known allergy/sensitivity or any hypersensitivity to components of study TB drugs or their formulation.
- Active drug, alcohol use or dependence; or mental illness (e.g., major depression) that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Known history of acute intermittent porphyria.
- Other medical conditions (e.g., severe uncontrolled diabetes, liver or kidney disease, blood disorders, peripheral neuritis, chronic diarrhea) in which the current clinical condition of the participant is likely to prejudice the response to, or assessment of, treatment.
Trial locations and contacts
6 sites in 5 countries.
6 sites in 5 countries
Haiti1 site
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, HT-6110
About this study
Official title: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
The purpose of this study was to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB).
Read the detailed description
This study compared a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB).
Randomization was stratified based on HIV status and the presence of advanced disease as determined by chest X-ray.
Participants were randomized to one of three arms:
- Arm 1 (Experimental): rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + CFZ 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks
- Arm 2 (SOC): rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks
- Arm C (PK-only subgroup): PHZE + CFZ 100 mg once daily for 4 weeks; then remain on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks)
All participants received pyridoxine (vitamin B6) with each dose of isoniazid (INH) based on current local, national or international dosing guidelines.
Arm 1 participants were treated for 13 weeks (including a 2-week CFZ loading dose of 300 mg daily). Arm 2 participants were treated for 26 weeks, and Arm C participants were treated for 4 weeks.
All participants in Arms 1, 2, and C were followed from randomization to Week 65.
On June 1, 2023, the Data and Safety Monitoring Board (DSMB) recommended that the study permanently close to accrual because of the high rate of treatment failure and TB recurrence. The A5362 team, NIAID and DAIDS leadership, and ACTG leadership concurred with the DSMB's recommendation and the study was closed to accrual on June 2, 2023. A letter of amendment was created that extended follow-up to 117 weeks for some participants in Arm 1.
Due to the early close to accrual, a primary analysis report forming the basis of the primary trial manuscript used data collected at study visits up to and including the date when the last enrolled participant completed the week 26 study visit (September 25. 2023). Another final analysis was performed using data collected at study visits up to the date when the last enrolled participant completed the week 65 assessment.
Study visits included physical examinations; blood, urine, and/or sputum collection; chest X-rays; and electrocardiograms (ECG).
- Conditions
- HIV, Tuberculosis
- Being tested
- Rifapentine, Rifampicin, Isoniazid, Pyrazinamide, Ethambutol
- Keywords
- rifapentine, clofazimine, drug-susceptible tuberculosis, tuberculosis treatment shortening
- Medical subject headings
- Tuberculosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RifapentineDrug
1200 mg once daily
RifampicinDrug
600 mg once daily
IsoniazidDrug
300 mg once daily
PyrazinamideDrug
1000mg once daily if weight is 40 to <55kg; 1500mg once daily if weight is 55 to <71kg; 2000mg once if weight is ≥71kg
EthambutolDrug
800 mg once daily if weight is 40 to <55kg; 1200 mg once daily if weight is 55 to <71kg; 1600mg once if weight is ≥71kg
Clofazimine loading doseDrug
300 mg once daily for 2 weeks (loading dose), then 100 mg once daily
Clofazimine 100 MGDrug
100 mg once daily
| Study group | Role | What they receive |
|---|---|---|
| Arm 1: Experimental | Experimental | Participants received rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks. Receives: Drug: Rifapentine; Drug: Isoniazid; Drug: Pyrazinamide; Drug: Ethambutol; Drug: Clofazimine loading dose |
| Arm 2: Standard of care | Active comparator | Participants received rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks. Receives: Drug: Rifampicin; Drug: Isoniazid; Drug: Pyrazinamide; Drug: Ethambutol |
| Arm C: PK only subgroup | Experimental | Participants received PHZE + CFZ 100 mg once daily for 4 weeks; then remained on study, and were treated with off study medications according to local SOC (RHZE for 4 weeks; then RH for 18 weeks). Receives: Drug: Rifapentine; Drug: Isoniazid; Drug: Pyrazinamide; Drug: Ethambutol; Drug: Clofazimine 100 MG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to 12 Weeks Stable Culture Conversion in Liquid Media
The time of stable culture conversion was the visit corresponding to the first of two consecutive negative cultures without an intervening positive, and/or visits wherein the participant was unable to produce sputum and had no signs of active TB.
If a participant did not culture convert, they were censored at their last culture result (regardless of result). If a participant died before conversion they were censored at 12 weeks. Participants who were lost to follow-up prior to 12 weeks with their last culture being positive were censored at 12 weeks (i.e. assumed they did not have a culture conversion by week 12), and participants who were lost to follow-up prior to 12 weeks with their last culture being negative were censored at the last sampling visit for which they had a valid culture result.
Measured: From Entry through Week 12
Participants Experiencing Any Grade 3 or Higher Adverse Event (AE) That is at Least a One Grade Increase From Baseline Over 65 Weeks
An adverse event is any unfavorable and unintended sign, symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution.
Adverse events are graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. AE grading was per Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table V2.1, Corrected Version 2.1, July 2017)
The primary manuscript outcome measure includes data through week 65 up to September 25, 2023
Measured: From entry through Week 65
Secondary outcomes (26)
Proportion of Participants With Favorable Clinical/Bacteriologic Outcome (Definition A) at 65 Weeks Post-randomization
Favorable Outcome are:
- liquid culture negative at week 65
- without signs or symptoms of ongoing active TB and unable to produce sputum at 65 weeks
- who at the end of the follow-up period are clinically without signs/symptoms of ongoing active TB and produce a sputum specimen that is contaminated in two liquid cultures without evidence of TB
Unfavorable:
- Absence of cure: Having a sputum sample at or after EOT that is culture-positive (any medium) with a second positive sample obtained 4 hours following the first sample.
- Death from any cause except for violent or accidental cause
- Had a positive culture for Mtb when last seen
- Had a treatment extension beyond nominal level due to clinically inadequate response
Unevaluable are:
- lost to follow-up during treatment or post-treatment with their last culture being negative for Mtb
- violent or accidental death
- becoming pregnant during their assigned active treatment and stop their assigned treatment.
Measured: From entry through Week 65
Proportion of Participants With Favorable Composite Outcome (Definition B) at 65 Weeks Post-randomization
Favorable Outcome are:
Same as definition A
Unfavorable:
Same as definition A and:
- lost to follow-up during treatment phase
- failing to complete treatment
- receiving any one or more of the following: extension of treatment beyond the nominal level, except to make up missed doses; re-starting treatment following >= 30 consecutive days lost to follow-up; a change in at least one drug in treatment regimen for any reason except re-infection, pregnancy, or temporary drug challenge
Unevaluable are:
- lost to follow-up after treatment phase, and not assessable at the end of follow-up, with their last culture being negative for Mtb
- Violent death or accidental death
- Women who become pregnant during their assigned active treatment and stop their assigned treatment
Measured: From entry through Week 65
Number of Participants Who Prematurely Discontinue Their Treatment Regimen Through 65 Weeks
Premature discontinuation is defined as discontinuation other than due to violent death, natural disaster, or administrative censoring
Measured: From entry through Week 65
Mean QTcF
QT interval measured as the average of three electrocardiogram (ECG) readings taken 5-10 minutes apart, corrected with Fridericia correction
Measured: Measured at Weeks 2, 8, and 13 (end of investigational treatment)
QTcF Interval Mean Change From Baseline
Mean change from baseline in mean QTcF at weeks 2, 8, and end of treatment (EOT)
Measured: Measured at baseline and Weeks 2, 8, and 13 (end of investigational treatment)
Categorized QTcF
Absolute QTcF was categorized as:< 480; ≥480 ms and <500 ms; ≥500 ms
Measured: Week 2, 8, and Week 13
Categorized Change From Baseline
Categorized change from baseline as: change from baseline of <30 ms; change from baseline of ≥30 ms and <60 ms; change from baseline of ≥60 ms
Measured: Measured at Weeks 2, 8, and Week 13
Time to Stable Culture Conversion in Liquid Media Through Week 65
Defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB
Measured: From entry through Week 65
Time to Stable Culture Conversion in Solid Media Through Week 65
The time of stable culture conversion was the visit corresponding to the first of two consecutive negative cultures without an intervening positive, and/or visits wherein the participant was unable to produce sputum and had no signs of active TB.
If a participant did not culture convert, they were censored at their last culture result (regardless of result). If a participant died before conversion, the death was considered as a competing event. Participants who were lost to follow-up prior to 65 weeks with their last culture being positive were censored at 65 weeks (i.e. assumed they did not have a culture conversion by week 65), and participants who were lost to follow-up prior to 65 weeks with their last culture being negative were censored at the last sampling visit for which they had a valid culture result.
Adjusted model adjusts for HIV-1 status (positive/negative) and TB Disease at Screening (Advanced/Not Advanced).
Measured: From entry through Week 65
Number of Participants Achieving Stable Liquid Culture Conversion by Week 8
Defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB
Measured: From entry through Week 8
Number of Participants Achieving Stable Solid Culture Conversion by Week 8
Defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB
Measured: From entry through Week 8
Number of Participants With One or More Serious Adverse Events (SAEs)
Cumulative proportion with at least one Serious Adverse Event (SAE)
A SAE is defined as any untoward medical occurrence that:
- Results in death
- Is life-threatening
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Is an important medical event that many not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above.
Measured: From entry through Week 65
Number of Participants Achieving Stable Solid Culture Conversion by Week 12
Defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB
Measured: From entry through Week 12
Median Time (Days) to Positivity in Liquid Culture (MGIT)
Time (days) to positivity in liquid culture (MGIT) is defined as the number of days it takes for the culture to produce results up to a max of 42 days. For negative culture results, time to positivity is imputed as 42 days.
Measured: From screening, entry, weeks 1, 2, 3, 4, 6, 8, 10, 12
Change in Chest X-ray Score From Baseline to End of Treatment in Each Arm
The chest X-ray was posterior-anterior. Extent of disease (limited to one lobe or region, unilateral, bilateral, or diffuse) and cavitation status (cavities present [location] or absent) was documented by validated numerical score (percent of total lung affected by any pathology + 40 if cavitation is present; 0 = No percent affected, 140 = entire lung is affected + cavitation is present) for grading chest X-ray in adult smear-positive pulmonary TB (Thorax 2010; 65(10):863-9).
Analysis was conducted based on site readings of CXR
Measured: Entry, End of Treatment (Week 13 for Arm 1 and Week 26 for Arm 2)
Proportion of Participants Who Have a TB Relapse, From End of Treatment Until Week 65
The time of relapse is defined as the time from end of treatment until the first sputum sample that is culture positive in liquid or solid media for an Mtb strain that has matching genotype with the baseline isolate (as determined by whole genome sequencing). A second positive sputum sample obtained at least 4 hours following the first sputum collection is required to confirm a relapse. If the second sputum sample was negative, this was not counted as a relapse. If a participant was lost to follow-up without a second sputum sample confirmation of relapse (including contaminated or missing), it was counted as a relapse.
Whole genome sequencing of samples, which is necessary to assess TB relapse, was not performed due to lack of funding. There is no plan to test these samples in the future.
Measured: From end of treatment (week 13 for Arm 1; week 26 for Arm 2) to week 65
Cumulative Proportion of Participants Who Have a TB Recurrence, From End of Treatment Until Week 65
The time of recurrence is defined as the time from end of treatment until the first sputum sample that is culture positive in liquid or solid media. A second positive sputum sample obtained at least 4 hours following the first sputum collection is required to confirm a recurrence. If the second sputum sample was negative, this will not be counted as a recurrence. If a participant was lost to follow-up without a second sputum sample confirmation of recurrence (including contaminated or missing), it was counted as a recurrence.
Participants at risk for recurrence where those who were stable culture conversions by end of treatment.
Measured: From end of treatment (week 13 for Arm 1; week 26 for Arm 2) to week 65
Pharmacokinetic Parameter for CFZ: Minimum Concentration (Cmin)
Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13.
Measured: Measured at Weeks 2 and 13
Pharmacokinetic Parameter for CFZ: Maximum Concentration (Cmax)
Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13.
Measured: Measured at Weeks 2 and 13
Pharmacokinetic Parameter for CFZ: Time of Cmax (Tmax)
Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13.
Measured: Measured at Weeks 2 and 13
Pharmacokinetic Parameter for CFZ: Area Under the Concentration Curve (AUC0-24h)
Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13.
Measured: Measured at Weeks 2 and 13
Mean Change From Baseline in Skin Pigmentation (Colorimetric L*)
The median of triplicate measurements of Inner Arm, and Face (median of all measurements from the Chin, Forehead, Left Cheek, and Right Cheek). L represents lightness (0 = black, 100 = white).
Further data processing removed values if one of the triplicates differed more than 5% of the median.
Measured: Entry, Weeks 8, 13, 26, and 65
Mean Change From Baseline in Skin Pigmentation (Colorimetric a*)
The median of triplicate measurements of Inner Arm, and Face (median of all measurements from the Chin, Forehead, Left Cheek, and Right Cheek). The a* parameter represents the balance between red and green. Positive values of a* indicate a reddish tone, while negative values indicate a greenish tone. (-128 = Green, 127 = Red).
Further data processing removed values if one of the triplicates differed more than 5% of the median.
Measured: Entry, Weeks 8, 13, 26, and 65
Mean Change From Baseline in Skin Pigmentation (Colorimetric b*)
The median of triplicate measurements of Inner Arm, and Face (median of all measurements from the Chin, Forehead, Left Cheek, and Right Cheek). The b* parameter represents the balance between yellow and blue. Positive values of b* indicate a yellowish tone, while negative values indicate a bluish tone (-128 = Blue, 127 = Yellow).
Further data processing removed values if one of the triplicates differed more than 5% of the median.
Measured: Entry, Weeks 8, 13, 26, and 65
Change From Baseline in Participant-reported Changes in Skin Pigment Related to Perceived Skin Hyperpigmentation
Subjective questionnaire asked the following questions :
1.) On a scale from 0 to 10: (0 being none and 10 being most significant possible) How would you rate any change in the coloration of your skin since you began TB treatment?
Measured: Entry, Weeks 8, 13, 26, and 65
Change From Baseline in Participant-reported Distress Caused by Change in Skin Pigment Related to Perceived Skin Hyperpigmentation
Subjective questionnaire asked the following questions:
On a scale from 0 to 10: (0 being none and 10 being worst possible) How would you rate your distress to skin coloration changes since you began TB treatment, if any?
Measured: Entry, Weeks 8, 13, 26, and 65
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2020
- Study start5 Nov 2021
- Primary completion24 Jun 2024
- Study completion24 Jun 2025
Why it stopped: Accrual was permanently closed due to futility in the experimental arm on June 22, 2023. Follow-up in the experimental arm was extended to 117 weeks.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HIVStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 104 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- John Metcalfe, MD, PhD, MPH, Study chair, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04311502
- Sponsor's protocol ID
- ACTG A5362
- Other IDs
- 30148
- Status last verified
- Jun 2026
- First submitted
- 5 Mar 2020
- Last updated
- 8 Jul 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie results in the publication, after deidentification.
Publications
Mugodhi F, Kanyama C, Makiya F, Metcalfe J, Potani C, Scarsi KK, Weir I, Furin J. "Six months is a lot of time to lie": Anticipated stigma, disclosure and treatment preferences among participants in a tuberculosis therapeutic trial. Res Sq [Preprint]. 2025 Dec 22:rs.3.rs-8277920. doi: 10.21203/rs.3.rs-8277920/v1.
PubMed 41510291Metcalfe JZ, Weir IR, Scarsi KK, Mendoza-Ticona A, Pierre S, Hall L, Leon-Cruz J, Svensson EM, Koele SE, Samaneka W, Kanyama C, Yohane M, Nevrekar N, Ntsalaze B, Marc JB, Goth M, Maartens G, Chaisson R; ACTG A5362 study team. A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial. Lancet Infect Dis. 2026 Jan;26(1):46-54. doi: 10.1016/S1473-3099(25)00436-0. Epub 2025 Sep 4.
PubMed 40915311
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
- ClinicalTrials.gov ID
- NCT04311502
- Acronym / sponsor ID
- ACTG A5362
- Conditions
- HIV, Tuberculosis
- Keywords
- rifapentine, clofazimine, drug-susceptible tuberculosis, tuberculosis treatment shortening
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Accrual was permanently closed due to futility in the experimental arm on June 22, 2023. Follow-up in the experimental arm was extended to 117 weeks.
- Enrolment
- 104 participants (actual)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- 5 Nov 2021 (actual)
- Primary completion
- 24 Jun 2024 (actual)
- Study completion
- 24 Jun 2025 (actual)
- First posted
- 17 Mar 2020 (actual)
- Results
- Posted 27 Aug 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB).
Detailed description
This study compared a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB).
Randomization was stratified based on HIV status and the presence of advanced disease as determined by chest X-ray.
Participants were randomized to one of three arms:
- Arm 1 (Experimental): rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + CFZ 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks
- Arm 2 (SOC): rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks
- Arm C (PK-only subgroup): PHZE + CFZ 100 mg once daily for 4 weeks; then remain on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks)
All participants received pyridoxine (vitamin B6) with each dose of isoniazid (INH) based on current local, national or international dosing guidelines.
Arm 1 participants were treated for 13 weeks (including a 2-week CFZ loading dose of 300 mg daily). Arm 2 participants were treated for 26 weeks, and Arm C participants were treated for 4 weeks.
All participants in Arms 1, 2, and C were followed from randomization to Week 65.
On June 1, 2023, the Data and Safety Monitoring Board (DSMB) recommended that the study permanently close to accrual because of the high rate of treatment failure and TB recurrence. The A5362 team, NIAID and DAIDS leadership, and ACTG leadership concurred with the DSMB's recommendation and the study was closed to accrual on June 2, 2023. A letter of amendment was created that extended follow-up to 117 weeks for some participants in Arm 1.
Due to the early close to accrual, a primary analysis report forming the basis of the primary trial manuscript used data collected at study visits up to and including the date when the last enrolled participant completed the week 26 study visit (September 25. 2023). Another final analysis was performed using data collected at study visits up to the date when the last enrolled participant completed the week 65 assessment.
Study visits included physical examinations; blood, urine, and/or sputum collection; chest X-rays; and electrocardiograms (ECG).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm 1: Experimental | Experimental | Drug: Rifapentine, Drug: Isoniazid, Drug: Pyrazinamide, Drug: Ethambutol, Drug: Clofazimine loading doseParticipants received rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks. |
| Arm 2: Standard of care | Active comparator | Drug: Rifampicin, Drug: Isoniazid, Drug: Pyrazinamide, Drug: EthambutolParticipants received rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks. |
| Arm C: PK only subgroup | Experimental | Drug: Rifapentine, Drug: Isoniazid, Drug: Pyrazinamide, Drug: Ethambutol, Drug: Clofazimine 100 MGParticipants received PHZE + CFZ 100 mg once daily for 4 weeks; then remained on study, and were treated with off study medications according to local SOC (RHZE for 4 weeks; then RH for 18 weeks). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (29 listed)
- Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:
- Pulmonary TB diagnosed without known INH resistance (e.g., by LPA or Xpert) and without known RIF resistance (e.g., by either LPA or Xpert).
- Absence of HIV-1 infection, as documented by any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, within 30 days prior to entry OR HIV-1 infection, documented by any licensed rapid HIV test or HIV-1 E/CIA test kit at any time prior to entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. Two or more HIV-1 RNA viral loads of >1,000 copies/mL are also acceptable as documentation of HIV-1 infection.
- For participants living with HIV, CD4+ cell count ≥100 cells/mm^3, obtained within 30 days prior to study entry at any network-approved non-US laboratory that is Immunology Quality Assessment (IQA) certified.
- For participants living with HIV must be currently receiving or planning to initiate antiretroviral therapy (ART) at or before study week 8.
Key exclusion criteria (13 listed)
- More than 5 days of treatment directed against active TB for the current TB episode preceding study entry.
- Pregnant or breast-feeding.
- Unable to take oral medications.
- Current receipt of clofazimine or bedaquiline or known receipt of clofazamine or bedaquiline at any time in the past.
- Corrected QT based on the Fridericia correction method (QTcF) interval >450 ms for men or >470 ms for women within 30 days prior to entry.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rifapentine1200 mg once daily | Drug | Arm 1: Experimental, Arm C: PK only subgroup |
| Rifampicin600 mg once daily | Drug | Arm 2: Standard of care |
| Isoniazid300 mg once daily | Drug | Arm 1: Experimental, Arm 2: Standard of care, Arm C: PK only subgroup |
| Pyrazinamide1000mg once daily if weight is 40 to <55kg; 1500mg once daily if weight is 55 to <71kg; 2000mg once if weight is ≥71kg | Drug | Arm 1: Experimental, Arm 2: Standard of care, Arm C: PK only subgroup |
| Ethambutol800 mg once daily if weight is 40 to <55kg; 1200 mg once daily if weight is 55 to <71kg; 1600mg once if weight is ≥71kg | Drug | Arm 1: Experimental, Arm 2: Standard of care, Arm C: PK only subgroup |
| Clofazimine loading dose300 mg once daily for 2 weeks (loading dose), then 100 mg once daily | Drug | Arm 1: Experimental |
| Clofazimine 100 MG100 mg once daily | Drug | Arm C: PK only subgroup |
Primary outcome
Time to 12 Weeks Stable Culture Conversion in Liquid Media
Time frame: From Entry through Week 12
The time of stable culture conversion was the visit corresponding to the first of two consecutive negative cultures without an intervening positive, and/or visits wherein the participant was unable to produce sputum and had no signs of active TB. If a participant did not culture convert, they were censored at their last culture result (regardless of result). If a participant died before conversion they were censored at 12 weeks. Participants who were lost to follow-up prior to 12 weeks with their last culture being positive were censored at 12 weeks (i.e. assumed they did not have a culture conversion by week 12), and participants who were lost to follow-up prior to 12 weeks with their last culture being negative were censored at the last sampling visit for which they had a valid culture result.
Participants Experiencing Any Grade 3 or Higher Adverse Event (AE) That is at Least a One Grade Increase From Baseline Over 65 Weeks
Time frame: From entry through Week 65
An adverse event is any unfavorable and unintended sign, symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. Adverse events are graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. AE grading was per Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table V2.1, Corrected Version 2.1, July 2017) The primary manuscript outcome measure includes data through week 65 up to September 25, 2023
26 secondary outcomes
Proportion of Participants With Favorable Clinical/Bacteriologic Outcome (Definition A) at 65 Weeks Post-randomization
Time frame: From entry through Week 65
Proportion of Participants With Favorable Composite Outcome (Definition B) at 65 Weeks Post-randomization
Time frame: From entry through Week 65
Number of Participants Who Prematurely Discontinue Their Treatment Regimen Through 65 Weeks
Time frame: From entry through Week 65
Mean QTcF
Time frame: Measured at Weeks 2, 8, and 13 (end of investigational treatment)
QTcF Interval Mean Change From Baseline
Time frame: Measured at baseline and Weeks 2, 8, and 13 (end of investigational treatment)
Categorized QTcF
Time frame: Week 2, 8, and Week 13
Categorized Change From Baseline
Time frame: Measured at Weeks 2, 8, and Week 13
Time to Stable Culture Conversion in Liquid Media Through Week 65
Time frame: From entry through Week 65
Time to Stable Culture Conversion in Solid Media Through Week 65
Time frame: From entry through Week 65
Number of Participants Achieving Stable Liquid Culture Conversion by Week 8
Time frame: From entry through Week 8
Number of Participants Achieving Stable Solid Culture Conversion by Week 8
Time frame: From entry through Week 8
Number of Participants With One or More Serious Adverse Events (SAEs)
Time frame: From entry through Week 65
Number of Participants Achieving Stable Solid Culture Conversion by Week 12
Time frame: From entry through Week 12
Median Time (Days) to Positivity in Liquid Culture (MGIT)
Time frame: From screening, entry, weeks 1, 2, 3, 4, 6, 8, 10, 12
Change in Chest X-ray Score From Baseline to End of Treatment in Each Arm
Time frame: Entry, End of Treatment (Week 13 for Arm 1 and Week 26 for Arm 2)
Proportion of Participants Who Have a TB Relapse, From End of Treatment Until Week 65
Time frame: From end of treatment (week 13 for Arm 1; week 26 for Arm 2) to week 65
Cumulative Proportion of Participants Who Have a TB Recurrence, From End of Treatment Until Week 65
Time frame: From end of treatment (week 13 for Arm 1; week 26 for Arm 2) to week 65
Pharmacokinetic Parameter for CFZ: Minimum Concentration (Cmin)
Time frame: Measured at Weeks 2 and 13
Pharmacokinetic Parameter for CFZ: Maximum Concentration (Cmax)
Time frame: Measured at Weeks 2 and 13
Pharmacokinetic Parameter for CFZ: Time of Cmax (Tmax)
Time frame: Measured at Weeks 2 and 13
Pharmacokinetic Parameter for CFZ: Area Under the Concentration Curve (AUC0-24h)
Time frame: Measured at Weeks 2 and 13
Mean Change From Baseline in Skin Pigmentation (Colorimetric L*)
Time frame: Entry, Weeks 8, 13, 26, and 65
Mean Change From Baseline in Skin Pigmentation (Colorimetric a*)
Time frame: Entry, Weeks 8, 13, 26, and 65
Mean Change From Baseline in Skin Pigmentation (Colorimetric b*)
Time frame: Entry, Weeks 8, 13, 26, and 65
Change From Baseline in Participant-reported Changes in Skin Pigment Related to Perceived Skin Hyperpigmentation
Time frame: Entry, Weeks 8, 13, 26, and 65
Change From Baseline in Participant-reported Distress Caused by Change in Skin Pigment Related to Perceived Skin Hyperpigmentation
Time frame: Entry, Weeks 8, 13, 26, and 65
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41510291Mugodhi F, Kanyama C, Makiya F, Metcalfe J, Potani C, Scarsi KK, Weir I, Furin J. "Six months is a lot of time to lie": Anticipated stigma, disclosure and treatment preferences among participants in a tuberculosis therapeutic trial. Res Sq [Preprint]. 2025 Dec 22:rs.3.rs-8277920. doi: 10.21203/rs.3.rs-8277920/v1.
- Derived from this study: PubMed 40915311Metcalfe JZ, Weir IR, Scarsi KK, Mendoza-Ticona A, Pierre S, Hall L, Leon-Cruz J, Svensson EM, Koele SE, Samaneka W, Kanyama C, Yohane M, Nevrekar N, Ntsalaze B, Marc JB, Goth M, Maartens G, Chaisson R; ACTG A5362 study team. A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial. Lancet Infect Dis. 2026 Jan;26(1):46-54. doi: 10.1016/S1473-3099(25)00436-0. Epub 2025 Sep 4.
- DAIDS AE Grading TableLink provided by the sponsor.
- Manual for Expedited Reporting of Adverse Events to DAIDSLink provided by the sponsor.
- A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosisLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Individual participant data that underlie results in the publication, after deidentification.
Related trials for HIV
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John Metcalfe, MD, PhD, MPH study chair
University of California, San Francisco
6 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Rifapentine, Rifampicin and Isoniazid in people with HIV and Tuberculosis, run by National Institute of Allergy and Infectious Diseases (NIAID) at 6 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 29 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Malawi, Haiti, India, South Africa, Zimbabwe. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Aug 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to 12 Weeks Stable Culture Conversion in Liquid Media (time frame: From Entry through Week 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04311502, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.